Calcium Modification Techniques in Coronary Artery Disease

Understanding Coronary Artery Calcification

Coronary artery calcification is a reliable marker of coronary atherosclerosis and vascular age, making it robust for risk assessment and prediction of future cardiovascular events in asymptomatic patients 1
Coronary artery calcification represents approximately 20% of the total atherosclerotic burden, as not all plaques contain calcium 1
Coronary artery calcification is superior to traditional risk factor assessments for informing diagnosis and is consistently the single best predictor of atherosclerotic cardiovascular disease risk compared to other nontraditional markers 1

The Agatston score is the most widely used coronary artery calcium scoring system in clinical practice and research 1
Coronary artery calcium scoring may be considered to improve risk classification around treatment decision thresholds (Class IIb C recommendation) 2, 3
When coronary artery calcification findings are available from previous chest CT scans, using these findings to enhance risk stratification and guide treatment of modifiable risk factors should be considered (Class IIa C recommendation) 2, 3

In patients with refractory angina leading to poor quality of life and with documented or suspected ANOCA/INOCA, invasive coronary functional testing is recommended to define endotypes and appropriate treatment (Class I B recommendation) 2, 3, 4
Calcium channel blockers are recommended for the treatment of isolated vasospastic angina to control symptoms and prevent ischemia and potentially fatal complications (Class I A recommendation) 2, 3, 4
Long-acting calcium channel blockers are often preferable to long-acting nitrates for maintenance therapy due to their sustained 24-hour effects 5
Nitrates should be considered to prevent recurrent episodes of vasospastic angina (Class IIa B recommendation) 2, 3, 4
Sublingual nitroglycerin or nitroglycerin spray is recommended for immediate relief of angina 5
In patients with evidence of overlapping endotypes, combination therapy with nitrates, calcium channel blockers, and other vasodilators may be considered (Class IIb B recommendation) 2, 3, 4
Beta-blockers with vasodilatory effects have neutral or beneficial effects on metabolic parameters, particularly important in patients with diabetes 6
For the management of microvascular angina associated with reduced coronary/myocardial blood flow reserve, beta-blockers should be considered for symptom control (Class IIa B recommendation) 2, 4
ACE inhibitors should be considered for symptom control in patients with endothelial dysfunction (Class IIa B recommendation) 2, 4

Patients with diabetes mellitus often have more extensive coronary calcification and complex coronary anatomy 6
Vasodilating beta-blockers may be preferred in patients with diabetes to avoid adverse metabolic effects 6
Ranolazine appears to reduce HbA1c by approximately 0.5% to 0.7% in addition to its antianginal effects, with enhanced effects in patients with poorly controlled diabetes 6

Mobile health interventions are recommended to improve patient adherence to healthy lifestyles and medical therapy (Class I A recommendation) 2, 3, 4
Simplifying medication regimens is recommended to increase patient adherence to medications (Class I B recommendation) 2, 4
Behavioral interventions are recommended to improve adherence (Class I B recommendation) 2, 4